HemaCare Plays Mission Critical Role in Global Cellular Therapy Development

T-cells attacking a cancer cell. 

 (Los Angeles – September 12, 2017)  HemaCare Corporation (OTCBB: HEMA), For many years, HemaCare has been at the epicenter of cellular therapy, immunotherapy, and regenerative medicine research by providing researchers from biotech and pharma companies with mission critical human biological materials from reliable and recallable donors. This includes process development material for autologous therapies (patient’s own cells used to treat disease), as well as supplying starting material for allogeneic cell therapies (healthy donor material used to create “off the shelf” treatments).  The ability to manipulate immune cells and reprogram them to target cancer and other diseases represents a new era in medicine, preceded by years of research and development using primary human cells from donors, including those collected and processed by HemaCare.

Our clients continue to request our expertise and rely upon our ability to provide cGMP collections as their development efforts move into advanced stages of development, including clinical trials and manufacturing of pharmaceutical-grade cells. With a strong global research and development pipeline, the pace of approvals for cellular therapy is poised to increase, and it is an exciting time not only for our customers, but for the many patients who will benefit from these revolutionary therapies.

“HemaCare is proud to continue playing a key role supporting the research and process development of therapies at various stages ranging from initial research all the way through commercialization of our clients’ projects,” said Pete van der Wal, HemaCare’s Chief Executive Officer. “HemaCare is thrilled to see the hard work and investment pay off for the benefit of patients all over the world, and congratulates the dedicated teams of scientists and doctors who are making these therapies a reality.”